U.S. markets open in 4 hours 23 minutes
  • S&P Futures

    4,272.50
    -4.25 (-0.10%)
     
  • Dow Futures

    33,929.00
    -34.00 (-0.10%)
     
  • Nasdaq Futures

    13,475.25
    -18.00 (-0.13%)
     
  • Russell 2000 Futures

    1,989.70
    +0.60 (+0.03%)
     
  • Crude Oil

    89.16
    +1.05 (+1.19%)
     
  • Gold

    1,779.10
    +2.40 (+0.14%)
     
  • Silver

    19.69
    -0.04 (-0.21%)
     
  • EUR/USD

    1.0175
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    2.8930
    0.0000 (0.00%)
     
  • Vix

    20.33
    +0.64 (+3.25%)
     
  • GBP/USD

    1.2059
    +0.0008 (+0.06%)
     
  • USD/JPY

    135.2290
    +0.1390 (+0.10%)
     
  • BTC-USD

    23,454.90
    -354.68 (-1.49%)
     
  • CMC Crypto 200

    557.68
    -15.14 (-2.64%)
     
  • FTSE 100

    7,506.75
    -9.00 (-0.12%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 12 newly-hired employees options to purchase an aggregate of 97,000 shares of Akebia's common stock on February 28, 2022, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

The options have an exercise price of $2.16 per share, which is equal to the closing price of Akebia's common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301494502.html

SOURCE Akebia Therapeutics